Navigation Links
Developed new method to diagnose hereditary breast and ovarian cancer
Date:1/16/2013

Researchers of the Catalan Institute of Oncology (ICO) at the Bellvitge Biomedical Research Institute (IDIBELL) have developed and validated a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The model is based on a genetic and bioinformatic analysis which has been proved very effective. The new protocol has been described in an article published in the European Journal of Human Genetics.

In recent years, new advances in sequencing techniques have involved the development of new platforms for nucleic acid sequencing, called mass sequencing platforms or next-generation sequencing. These technological improvements have brought a revolution in biomedical research, in the field of genetics and genomics. The emergence of next-generation sequencers and the possibility of combining samples from different patients using identifiers have allowed to adapt these new technologies in the field of the genetic diagnosis.

Using a platform of last generation mass sequencing, the team led by the researcher Conxi Lzaro, from the Hereditary Cancer Program at the ICO and IDIBELL, has developed a comprehensive protocol that allows to sequence all coding and adjacent regions of BRCA1 and BRCA2 genes, responsible for hereditary breast and ovarian cancer syndrome.

Mass sequencing algorithm

"This approach allows to identify all point mutations and small deletions and insertions analyzed, even in regions of high technical difficulty, such as homopolymeric regions", explains the ICO-IDIBELL researcher. The protocol developed is an own algorithm of mass sequencing and bioinformatics analysis that has been shown to be very efficient to detect all existing mutations and to eliminate false positives.

The validation of this algorithm to diagnose hereditary breast and ovarian cancer syndrome has shown a sensitivity and specificity of 100% in the analyzed samples, while reducing costs and time for obtaining the results.

Furthermore, the research team led by Lzaro has implemented the use of this approach for the responsible genes for hereditary colorectal cancer, such as familial polyposis and Lynch syndrome.

Up to ten percent of cancers are hereditary, which means that the genetic mutations predisposing to various types of tumors are transmitted from parents to offspring. The identification of these mutations is very important to prevent the occurrence of tumors in people who have familial predisposition.

The hereditary breast and ovarian cancer syndrome is one of the hereditary cancer types that affects more people. The disease is caused by mutations in the BRCA1 and BRCA2 genes. These mutations are also associated with other kind of cancers.


'/>"/>
Contact: Ral Toran
comunicacio@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Related medicine news :

1. Research shows efficacy of treatment model developed at Women & Infants
2. Power generation technology based on piezoelectric nanocomposite materials developed by KAIST
3. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
4. FDA clears test developed in partnership with VCU researcher
5. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
6. New Facebook app to detect pedophiles and criminals developed by Ben-Gurion U. researchers
7. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
8. Heroes of Chemistry: Developed new drugs and technology to cut heating and cooling bills
9. Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher
10. Strategy developed to improve delivery of medicines to the brain
11. Models developed from the PLCO may help identify at-risk patients for adverse smoking outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... ... weather here, many people will have to clear snow with snow blowers or shovels from ... they can be dangerous when used incorrectly. That’s why Amica Insurance is sharing ... snow blowers:, , When removing wet snow or debris from the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... engineers, and scientists from around the world, announces the launch of its newly ... and easy portal to research breakthroughs and trending news, vital information on upcoming ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound ... extension to RMT technology that delivers HD, dynamic, streaming ultrasound images and video ...
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is announcing their participation ... Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in ... program. , “We know it’s easy to get carried away when you’re ...
(Date:1/19/2017)... ... 19, 2017 , ... Dr. Andrew Lian-Jie Li ... trained Mohs and cosmetic surgeon. After extensive dermatology research training at the National ... in internal medicine at the Emory University and dermatology training at the University ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Report Details What can be ... going to grow at the fastest rates? This visiongain ... trends, opportunities and prospects. Our 190-page report provides ... areas in the industry and the future market prospects. ... the all the major categories of the ophthalmic devices ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... Opportunities for Leading Companies – our new study reveals ... discusses issues and events affecting the Alzheimer,s disease therapeutics ... to answer these key questions: - How is the ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin ... global anti-obesity drugs market is expected to grow at ... period and CAGR of 38.7% in the second half of the ... of 32.8% from 2016 to 2027. The market is estimated at ... in 2027. ...
Breaking Medicine Technology: